S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in
NASDAQ:STOK

Stoke Therapeutics Stock Forecast, Price & News

$67.32
-0.21 (-0.31 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$64.36
Now: $67.32
$67.61
50-Day Range
$49.08
MA: $58.88
$69.81
52-Week Range
$15.82
Now: $67.32
$71.58
Volume97,253 shs
Average Volume146,625 shs
Market Capitalization$2.25 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.63
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.

MarketRank

Overall MarketRank

1.40 out of 5 stars

Medical Sector

541st out of 1,923 stocks

Pharmaceutical Preparations Industry

272nd out of 773 stocks

Analyst Opinion: 2.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STOK
CUSIPN/A
CIKN/A
Phone781-430-8200
Employees56

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.86 per share

Profitability

Net Income$-32,330,000.00

Miscellaneous

Market Cap$2.25 billion
Next Earnings Date3/22/2021 (Estimated)
OptionableNot Optionable
$67.32
-0.21 (-0.31 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive STOK News and Ratings via Email

Sign-up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Stoke Therapeutics (NASDAQ:STOK) Frequently Asked Questions

How has Stoke Therapeutics' stock price been impacted by COVID-19?

Stoke Therapeutics' stock was trading at $19.73 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, STOK shares have increased by 241.2% and is now trading at $67.32.
View which stocks have been most impacted by COVID-19
.

Is Stoke Therapeutics a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Stoke Therapeutics stock.
View analyst ratings for Stoke Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Stoke Therapeutics?

Wall Street analysts have given Stoke Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Stoke Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Stoke Therapeutics' next earnings date?

Stoke Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 22nd 2021.
View our earnings forecast for Stoke Therapeutics
.

How were Stoke Therapeutics' earnings last quarter?

Stoke Therapeutics, Inc. (NASDAQ:STOK) released its quarterly earnings results on Thursday, November, 12th. The company reported ($0.41) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.41).
View Stoke Therapeutics' earnings history
.

What price target have analysts set for STOK?

8 brokers have issued 12 month price objectives for Stoke Therapeutics' shares. Their forecasts range from $49.00 to $72.00. On average, they expect Stoke Therapeutics' share price to reach $62.17 in the next year. This suggests that the stock has a possible downside of 7.7%.
View analysts' price targets for Stoke Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of Stoke Therapeutics' key competitors?

What other stocks do shareholders of Stoke Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology Group (MRVL) and Invitae (NVTA).

Who are Stoke Therapeutics' key executives?

Stoke Therapeutics' management team includes the following people:
  • Dr. Edward M. Kaye, CEO & Director (Age 72, Pay $668.37k)
  • Dr. Adrian R. Krainer Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board (Age 62, Pay $119.5k)
  • Mr. Stephen J. Tulipano CPA, CPA, MBA, Chief Financial Officer (Age 62, Pay $514.47k)
  • Ms. Isabel Aznarez Ph.D., Co-Founder, VP & Head of Biology (Age 49)
  • Dr. Huw M. Nash Ph.D., COO & Chief Bus. Officer (Age 54)
  • Ms. Joan Wood, Head of HR
  • Dr. Gene Liau, Exec. VP, Head of Research & Preclinical Devel. (Age 66)
  • Dr. Barry S. Ticho FACC, M.D., Ph.D., Chief Medical Officer (Age 61)
  • Ms. Shamim Ruff, Sr. VP of Regulatory Affairs & Quality (Age 61)
  • Ms. Nancy M. Wyant, VP & Head of Clinical Operations (Age 49)

When did Stoke Therapeutics IPO?

(STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Stoke Therapeutics' stock symbol?

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

Who are Stoke Therapeutics' major shareholders?

Stoke Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Pacer Advisors Inc. (0.00%). Company insiders that own Stoke Therapeutics stock include Apple Tree Partners Iv, LP, Arthur Tzianabos, Barry Ticho, Edward M Md Kaye, Gene Liau, Huw M Nash, Robin A Walker, Rtw Investments, Lp and Stephen J Tulipano.
View institutional ownership trends for Stoke Therapeutics
.

Which major investors are buying Stoke Therapeutics stock?

STOK stock was purchased by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have bought Stoke Therapeutics stock in the last two years include Apple Tree Partners Iv, LP, and Rtw Investments, Lp.
View insider buying and selling activity for Stoke Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Stoke Therapeutics?

Shares of STOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Stoke Therapeutics' stock price today?

One share of STOK stock can currently be purchased for approximately $67.32.

How big of a company is Stoke Therapeutics?

Stoke Therapeutics has a market capitalization of $2.25 billion. The company earns $-32,330,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. Stoke Therapeutics employs 56 workers across the globe.

What is Stoke Therapeutics' official website?

The official website for Stoke Therapeutics is www.stoketherapeutics.com.

How can I contact Stoke Therapeutics?

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company can be reached via phone at 781-430-8200 or via email at [email protected]

This page was last updated on 1/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.